Liquid biopsy testing is a rapidly developing clinical application that is largely driven by new and innovative technologies. Join us on February 21^st for this Liquid Biopsy seminar, where Oliver Wachter, Prof. Dr. med. Stefan Holdenrieder, Dr. Pierre-Jean Lamy and Dr. Alexander Sartori will will discuss how liquid biopsy testing is breaking new ground in cancer management. Register early as space is limited.

Program:

14:00 Arrival of participants

14:30 “Current possibilities in routine diagnostics and where are we going.” Oliver Wachter, Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ) Dr. Klein, Dr. Rost und Kollegen

15:15 “Preanalytical, analytical and clinical considerations for cfDNA diagnostics.” Prof. Dr. med. Stefan Holdenrieder, Director Institut für Laboratoriumsmedizin, Deutsches Herzzentrum München

15:45 Coffee Break

16:00 “Impact on treatment decision depending on method for Liquid Biopsy testing. Comparative study.” Dr. Pierre-Jean Lamy, LaboSud, Montpellier

16:45 “Ultra-sensitive detection of somatic mutations in Liquid Biopsy with the MassARRAY^® System.” Dr. Alexander Sartori, Manager Scientific Affairs, Agena Bioscience, Hamburg

17:30 Discussion and Buffet